Subcellular fractions are used in drug discovery and preclinical drug development to evaluate a new therapeutics’ in vitro metabolism.
According to the contract research organization (CRO), human and minipig have been added to the company’s list of species with dermal subcellular fractions available as standard test systems.
“Our biggest demand so far has come from European countries where animal use in biomedical/cosmetic research is highly restricted and most testing has to be performed in vitro,” Zell Woodworth, Products Division Director for Sekisui XenoTech, told us.
“Generally, customers who are interested in skin subcellular fractions are looking for local substrate loss or metabolite formation in the skin during transdermal/topical delivery of a drug,” Woodworth added.
Late last year, Sekisui XenoTech also expanded its test systems to include hepatic human lysosomes and rat tritosomes.
Additionally, in August of last year, the company announced supplementary hepatotoxicity screening assays and methodologies to its existing cytotoxicity contract research services.